Sanofi licenses rights to CureDM's Pancreate
CureDM Group Holdings LLC (metabolic disease treatments) has granted Sanofi-Aventis exclusive worldwide rights to develop, manufacture, and sell its Pancreate (proisletide) regenerative compound for Type I and II diabetes, as well as related drug candidates.
- Large Molecule
- Includes Royalty or Profit Split Information
- R&D and Marketing (Licensing)
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.